|
|
|
|
In patients with nonvalvular atrial fibrillation and in increased risk of stroke prophylaxis, apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg were all cost-effective alternatives to warfarin. The cost-effectiveness of novel oral anticoagulants was dependent on therapy pricing in the United States and neurological events associated with rivaroxaban 20 mg. |
|